PrihodDobitKGVKUVEBITDividendaDioniceTržišna kapitalizacijaDugovanjeObvezeTemeljni kapitalAAQSzaposleniciROEROAROCE
Vir Biotechnology Dionica

Vir Biotechnology ROA 2024

Vir Biotechnology ROA

−0,32

Ticker

VIR

ISIN

US92764N1028

WKN

A2PS0P

U godini 2024 povrat na ukupnu imovinu (ROA) od Vir Biotechnology iznosio je −0,32, povećanje za −274,11% u odnosu na 0,18 ROA prethodne godine.

Vir Biotechnology Aktienanalyse

Što radi Vir Biotechnology?

Vir Biotechnology Inc. is a biopharmaceutical company focused on the development of therapeutics to combat infectious diseases. The company was founded in 2016 by George Scangos, former CEO of Biogen, and Bob Nelsen, co-founder of Arch Venture Partners. History: Vir Biotechnology originated from a collaboration between Arch Venture Partners and the biotechnology incubator, The Infectious Disease Research Institute (IDRI), to develop therapeutics against Ebola viruses. In 2016, they founded Vir Biotechnology with an initial capital of $150 million from various investors, including SoftBank and the Bill & Melinda Gates Foundation. The company received an additional capital injection of $250 million in 2018 and went public in the same year. Business model: Vir Biotechnology builds on its proprietary technology platform, which focuses on antibody identification. The company collaborates with various partners, including Biogen and Alnylam Pharmaceuticals, to utilize its technology for the development of therapeutics against infectious diseases such as COVID-19, influenza, rabbit fever, and the Zika virus. Vir Biotechnology also has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482. VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19 and is currently in phase 3 clinical trials. VIR-2703 is an inactive RNA vaccine developed for the prevention of COVID-19 and is currently in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine recently investigated in a phase 1/2a clinical trial. Divisions: Vir Biotechnology has focused on three main divisions: infectious diseases, immuno-oncology therapy, and neurodegenerative diseases. In the field of infectious diseases, the company works on the development of therapeutics against viruses such as COVID-19, respiratory syncytial virus (RSV), West Nile virus, and influenza virus. In the field of immuno-oncology therapy, the company works on the development of therapeutics against cancer. And in the field of neurodegenerative diseases, the company works on the development of therapeutics against diseases such as Alzheimer's and Parkinson's. Products: VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19. The antibody binds to the spike protein of the virus and blocks its interaction with ACE2 receptors in human cells. It is currently being tested in phase 3 clinical trials. VIR-2703 is a well-tolerated RNA vaccine developed for the prevention of COVID-19. It contains an inactivated form of the virus that stimulates the immune system to produce antibodies against the virus. It is currently being tested in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine developed to cover a broader spectrum of influenza viruses than conventional flu vaccines. The vaccine contains a combination of antibodies against various strains of the influenza virus and was recently investigated in a phase 1/2a clinical trial. Summary: Vir Biotechnology is a biopharmaceutical company focused on the development of therapeutics to combat infectious diseases. The company has a proprietary technology platform for antibody identification and collaborates with various partners to utilize this technology for the development of therapeutics against a variety of diseases. The company has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482, as well as research programs in the fields of immuno-oncology and neurodegeneration. The translation is: Vir Biotechnology Inc. is a biopharmaceutical company that focuses on the development of therapeutics to combat infectious diseases. The company was founded in 2016 by George Scangos, former CEO of Biogen, and Bob Nelsen, co-founder of Arch Venture Partners. History: Vir Biotechnology originated from a collaboration between Arch Venture Partners and the biotechnology incubator, The Infectious Disease Research Institute (IDRI), to develop therapeutics against Ebola viruses. In 2016, they founded Vir Biotechnology with an initial capital of $150 million from various investors, including SoftBank and the Bill & Melinda Gates Foundation. The company received an additional capital injection of $250 million in 2018 and went public in the same year. Business model: Vir Biotechnology builds on its proprietary technology platform, which focuses on antibody identification. The company collaborates with various partners, including Biogen and Alnylam Pharmaceuticals, to utilize its technology for the development of therapeutics against infectious diseases such as COVID-19, influenza, rabbit fever, and the Zika virus. Vir Biotechnology also has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482. VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19 and is currently in phase 3 clinical trials. VIR-2703 is an inactive RNA vaccine developed for the prevention of COVID-19 and is currently in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine recently investigated in a phase 1/2a clinical trial. Divisions: Vir Biotechnology has focused on three main divisions: infectious diseases, immuno-oncology therapy, and neurodegenerative diseases. In the field of infectious diseases, the company works on the development of therapeutics against viruses such as COVID-19, respiratory syncytial virus (RSV), West Nile virus, and influenza virus. In the field of immuno-oncology therapy, the company works on the development of therapeutics against cancer. And in the field of neurodegenerative diseases, the company works on the development of therapeutics against diseases such as Alzheimer's and Parkinson's. Products: VIR-7831 is a monoclonal antibody developed for the treatment of COVID-19. The antibody binds to the spike protein of the virus and blocks its interaction with ACE2 receptors in human cells. It is currently being tested in phase 3 clinical trials. VIR-2703 is a well-tolerated RNA vaccine developed for the prevention of COVID-19. It contains an inactivated form of the virus that stimulates the immune system to produce antibodies against the virus. It is currently being tested in phase 2 clinical trials. VIR-2482 is a universal influenza vaccine developed to cover a broader spectrum of influenza viruses than conventional flu vaccines. The vaccine contains a combination of antibodies against various strains of the influenza virus and was recently investigated in a phase 1/2a clinical trial. Summary: Vir Biotechnology is a biopharmaceutical company focused on the development of therapeutics to combat infectious diseases. The company has a proprietary technology platform for antibody identification and collaborates with various partners to utilize this technology for the development of therapeutics against a variety of diseases. The company has several pipeline programs in clinical development, including VIR-7831, VIR-2703, and VIR-2482, as well as research programs in the fields of immuno-oncology and neurodegeneration. Vir Biotechnology ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROA u detalje

Razumijevanje povrata na imovinu (ROA) od Vir Biotechnology

Povrat na imovinu (ROA) od Vir Biotechnology ključni je pokazatelj koji mjeri profitabilnost poduzeća u odnosu na ukupnu imovinu. Izračunava se dijeljenjem neto dobiti s ukupnom imovinom. Viši ROA ukazuje na učinkovito korištenje imovine za stvaranje dobiti i odražava učinkovitost upravljanja i financijsko zdravlje.

Usporedba iz godine u godinu

Usporedba ROA od Vir Biotechnology iz godine u godinu pruža uvid u operativnu učinkovitost i trendove u upotrebi imovine poduzeća. Rastući ROA pokazuje poboljšanu učinkovitost imovine i profitabilnost, dok smanjenje ROA može ukazivati na operativne ili financijske izazove.

Utjecaji na investicije

Investitori smatraju ROA od Vir Biotechnology ključnom metrikom za ocjenjivanje profitabilnosti i učinkovitosti poduzeća. Viši ROA znači da poduzeće efikasno koristi svoju imovinu za stvaranje dobiti, što ga čini potencijalno privlačnom investicijom.

Interpretacija fluktuacija ROA

Fluktuacije u ROA od Vir Biotechnology mogu se pripisati promjenama u neto dobiti, stjecanju imovine ili operativnoj učinkovitosti. Analiza ovih fluktuacija pomaže u ocjenjivanju financijske izvedbe, učinkovitosti upravljanja i strateškog financijskog pozicioniranja poduzeća.

Česta pitanja o Vir Biotechnology dionici

Koliki je povrat na imovinu (ROA) od Vir Biotechnology ove godine?

Stopa povrata na imovinu (ROA) za Vir Biotechnology iznosi ove godine −0,32 undefined.

Koliki je bio ROA od Vir Biotechnology u usporedbi s prošlom godinom?

ROA kompanije Vir Biotechnology se u usporedbi sa prošlom godinom promijenio za −274,11% .

Koje posljedice visoki ROA ima za investitore od Vir Biotechnology?

Visok ROA je povoljan za investitore Vir Biotechnology jer ukazuje na to da poduzeće učinkovito koristi svoju imovinu i ostvaruje dobru dobit.

Koje posljedice niski ROA ima za investitore od Vir Biotechnology?

Nizak ROA može biti nepovoljan za investitore Vir Biotechnology jer ukazuje na to da poduzeće nekorisno koristi svoju imovinu i moguće je da ostvaruje manju dobit.

Kakav utjecaj ima povećanje ROA od Vir Biotechnology na poduzeće?

Povećanje ROA od Vir Biotechnology može biti pokazatelj poboljšane učinkovitosti u korištenju imovine i veće profitabilnosti.

Kako smanjenje ROA od Vir Biotechnology utječe na poduzeće?

Smanjenje ROA od Vir Biotechnology može biti indikator slabije učinkovitosti pri korištenju imovine i manje profitabilnosti.

Koji su neki od faktora koji mogu utjecati na ROA od Vir Biotechnology?

Neki od faktora koji mogu utjecati na ROA od Vir Biotechnology uključuju, između ostalog, prihod, operativne troškove, strukturu imovine i prosjek industrije.

Zašto je ROA od Vir Biotechnology važan za investitore?

ROA od Vir Biotechnology je važan za investitore jer je pokazatelj profitabilnosti poduzeća i njegove učinkovitosti u korištenju imovine. Pruža investitorima informacije o tome koliko dobro poduzeće koristi svoja sredstva za ostvarivanje dobiti.

Koje strateške mjere Vir Biotechnology može poduzeti kako bi poboljšao ROA?

Da bi poboljšao ROA, Vir Biotechnology može poduzeti mjere kao što su smanjenje troškova, povećanje prihoda, optimizacija strukture imovine i diversifikacija svoje poslovne aktivnosti. Važno je da tvrtka provede temeljitu analizu svoje financijske situacije kako bi odredila najbolje strateške akcije za poboljšanje ROA.

Koliko dividende plaća Vir Biotechnology?

U posljednjih 12 mjeseci Vir Biotechnology je isplatio dividendu u iznosu od . To odgovara prinosu dividende od oko . Za sljedećih 12 mjeseci Vir Biotechnology će vjerojatno isplatiti dividendu u iznosu od 0 USD.

Kolika je dividendna prinosa od Vir Biotechnology?

Trenutni prinos dividende od Vir Biotechnology iznosi .

Kada Vir Biotechnology isplaćuje dividendu?

Vir Biotechnology isplaćuje dividende kvartalno. One se isplaćuju u mjesecima .

Koliko je sigurna dividenda od Vir Biotechnology?

Vir Biotechnology je isplatio dividendu svake godine u posljednjih 0 godina.

Kolika je dividenda od Vir Biotechnology?

Za nadolazećih 12 mjeseci očekuje se isplata dividendi u iznosu od 0 USD. To odgovara dividendnom prinosu od 0 %.

U kojem se sektoru nalazi Vir Biotechnology?

Vir Biotechnology se pripisuje sektoru 'Zdravlje'.

Wann musste ich die Aktien von Vir Biotechnology kaufen, um die vorherige Dividende zu erhalten?

Da bi primili posljednju dividendu od Vir Biotechnology od 14. 09. 2024. u iznosu od 0 USD, trebali ste imati dionicu u portfelju prije Ex-dana 14. 09. 2024..

Kada je Vir Biotechnology isplatio posljednju dividendu?

Posljednja isplata dividende izvršena je 14. 09. 2024..

Kolika je bila dividenda Vir Biotechnology u godini 2023?

U godini 2023 su od Vir Biotechnology 0 USD isplaćene kao dividende.

U kojoj valuti Vir Biotechnology isplaćuje dividendu?

Dividende od Vir Biotechnology isplaćuju se u USD.

Aktiensparpläne nude atraktivnu mogućnost za investitore za dugoročno stvaranje imovine. Jedna od glavnih prednosti je tzv. efekt prosječenja troškova: investirajući redovito fiksni iznos u dionice ili dioničke fondove, automatski se kupuje više udjela kada su cijene niske, a manje kada su visoke. To može dovesti do povoljnijeg prosječnog cijene po udjelu tijekom vremena. Osim toga, Aktiensparpläne omogućavaju i malim investitorima pristup skupim dionicama, jer mogu sudjelovati već s malim iznosima. Redovita investicija također promiče discipliniranu strategiju ulaganja i pomaže izbjeći emocionalne odluke, poput impulzivne kupnje ili prodaje. Pored toga, investitori profitiraju od potencijalnog povećanja vrijednosti dionica kao i od isplata dividendi koje mogu biti reinvestirane, što pojačava učinak kamatnog kamata i time rast uloženog kapitala.

Andere Kennzahlen von Vir Biotechnology

Naša analiza dionica Vir Biotechnology Prihod uključuje važne financijske pokazatelje kao što su prihod, dobit, P/E omjer, P/S omjer, EBIT, kao i informacije o dividendi. Također, razmatramo aspekte poput dionica, tržišne kapitalizacije, dugova, vlastitog kapitala i obveza Vir Biotechnology Prihod. Ako tražite detaljnije informacije o ovim temama, na našim podstranicama nudimo opsežne analize: